Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 7/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.52 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | XBP1 | P17861 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186717 | 0.94 | CACNA1B (0.54) | CACNA1BCACNA1HPGRFABP4MAPT | |
| SCHEMBL6177543 | 0.91 | CACNA1B (0.59) | CACNA1BCACNA1HPGRFABP4UTS2R | |
| SCHEMBL6177607 | 0.91 | CACNA1B (0.55) | CACNA1BCACNA1HPGRFABP4MAPT | |
| SCHEMBL6177731 | 0.91 | CACNA1B (0.65) | CACNA1BCACNA1HPGRFABP4UTS2R | |
| SCHEMBL6176052 | 0.91 | CACNA1B (0.53) | CACNA1BCACNA1HPGRFABP4MAPT | |
| SCHEMBL6174364 | 0.89 | CACNA1B (0.49) | CACNA1BCACNA1HPGRFABP4MAPT | |
| SCHEMBL6176083 | 0.88 | CACNA1B (0.57) | CACNA1BCACNA1HHPGDUTS2R | |
| SCHEMBL6178234 | 0.85 | CACNA1B (0.54) | CACNA1BCACNA1HPGRFABP4MAPT | |
| SCHEMBL6179473 | 0.85 | CACNA1B (0.54) | CACNA1BCACNA1HPGRFABP4HPGD | |
| SCHEMBL6542669 | 0.84 | UTS2R (0.53) | CACNA1BCACNA1HFABP4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | claimed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152893-A1 | Sulfonamides | UTS2R, PRSS2, STS | CACNA1B 3246/4885CACNA1H 3106/4885PGR 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.